These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Glycopeptide and oxacillin activity against Staphylococcus aureus isolates at a tertiary care center in Lebanon.
    Author: Kanj SS, Ghaleb PA, Araj GF.
    Journal: J Med Liban; 2004; 52(1):8-12. PubMed ID: 15881695.
    Abstract:
    BACKGROUND: Worldwide reports have noted the emergence of glycopeptide-intermediate Staphylococcus aureus (GISA). However, data from Lebanon is lacking. METHODS: We conducted a study to determine the minimum inhibitory concentrations (MICs) for oxacillin (OXA), vancomycin (VAN) and teicoplanin (TEC) against consecutive clinical isolates of S. aureus at a tertiary care center in Lebanon. The categorization of isolates as susceptible, intermediately-resistant, or resistant was based on the OXA agar screen plate (OS) and the 1 microg OXA disk diffusion (OD) according to the National Committee for Clinical Laboratory Standards (NCCLS) guidelines. The MICs of OXA, VAN and TEC against these isolates were determined using the E-test. RESULTS: We tested 147 S. aureus isolates, 108 of which were methicillin-resistant (MRSA) and 39 methicillin-susceptible (MSSA). The rar ges of MICs (microg/ml) among MRSA and MSSA isolates respectively were : OXA 1.5- > or = 256 and 0.19-3; VAN 1-3 and 1.5-3; TEC 0.094-3 and 0.19-2. The MIC50/90 (microg/ml) for MRSA versus MSSA isolates were, respectively: 24/ > or = 256 vs. 1/2 for OXA; 2/3 vs. 2/2 for VAN; 1/1.5 vs. 0.75/1.5 for TEC. CONCLUSION: This data indicates that despite the presence of high rates of MRSA (around 38%), these strains remain fully susceptible to VAN and TEC. We did not detect any GISA at this tertiary care referral medical center in Lebanon.
    [Abstract] [Full Text] [Related] [New Search]